Bionano guides FY2022 revenue $27.7-28M; updates TAM to $10B

Bionano Genomics, Inc.

2022-FY EPS reported -$0.46 revenue$27,802,000

FY2022 revenue expected $27.7M-$28.0M; breakdown: 57% systems/consumables, 21% software, 22% services.
Geographic revenue: Americas 50%, APAC 17%, EMEA 33%.
TAM estimated at $10B annually, with $3B from cell bioprocessing QC opportunity.
Target markets include 10,000 labs and 1,400 therapeutics companies for OGM adoption.

item 2.02 item 8.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Bionano Genomics, Inc. reported full year 2022 results: revenue $27.7 million and $28.0 million.

Period: full year 2022
Revenue: $27.7 million and $28.0 million
Result: preliminary results

Exact text from the filing

As previously announced on January 5, 2022, Bionano Genomics, Inc. (the “Company”), expects to report full year 2022 total revenue in the range of $27.7 million and $28.0 million.

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

Bionano Genomics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-004345

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.